Cross reactivity of serum antibody responses elicited by DNA vaccines expressing HA antigens from H1N1 subtype influenza vaccines in the past 30 years

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 10, 2013, Pages 2049-2059

  Almansour, Iman ^a   Chen, Huaiqing ^a   Wang, Shixia ^a   Lu, Shan ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Antibody; DNA vaccine; H1N1; Hemagglutinin; Influenza

Indexed keywords

DNA VACCINE; HORSERADISH PEROXIDASE; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; POLYETHYLENEIMINE;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN ANTIBODY REACTION; ARTICLE; CONTROLLED STUDY; CROSS REACTION; DRUG DESIGN; DRUG FORMULATION; DRUG SYNTHESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE GUN IMMUNIZATION; GENETIC TRANSFECTION; HA GENE; HEMAGGLUTINATION INHIBITION; HUMAN; HUMAN CELL; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; INFLUENZA A (H1N1); INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; RESIDUE ANALYSIS; SEASONAL VARIATION; VIRUS GENE; VIRUS ISOLATION; VIRUS NEUTRALIZATION; VIRUS STRAIN;

ANTIBODY; DNA VACCINE; H1N1; HEMAGGLUTININ; INFLUENZA;

ANIMALS; ANTIBODIES, VIRAL; CROSS REACTIONS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; RABBITS; VACCINES, DNA;

EID: 84885141966     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.25735     Document Type: Article

References (39)

1. Barik S. New treatments for influenza. BMC Med 2012;10:104; PMID:22973873; http://dx.doi.org/10.1186/1741-7015-10-104
2. Carrillo-Santisteve P, Ciancio BC, Nicoll A, Lopalco PL. The importance of influenza prevention for public health. Hum Vaccin Immunother 2012;8:89-95; PMID:22251992; http://dx.doi.org/10.4161/hv. 8.1.19066
3. Bardiya N, Bae JH. Influenza vaccines: recent advances in production technologies. Appl Microbiol Biotechnol 2005;67:299-305; PMID: 15660212; http://dx.doi.org/10.1007/s0025 3-004-1874-1
4. Sasaki S, Sullivan M, Narvaez CF, Holmes TH, Furman D, Zheng NY, et al. Limited efficacy of inactivated influenza vaccine in elderly individuals is associated with decreased production of vaccinespecific antibodies. J Clin Invest 2011;121:3109-19; PMID:21785218; http://dx.doi.org/10.1172/JCI57834
5. Ambrose CS, Levin MJ, Belshe RB. The relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adults. Influenza Other Respi Viruses 2011;5:67-75; PMID:21306569; http://dx.doi.org/10.1111/j. 1750-2659.2010.00183.x
6. Cox RJ, Brokstad KA, Ogra P Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand J Immunol 2004;59:1-15; PMID: 14723616; http://dx.doi.org/10.1111/j.0300-9475.2004.01382.x
7. Harris K, Ream R, Gao J, Eichelberger MC. Intramuscular immunization of mice with live influenza virus is more immunogenic and offers greater protection than immunization with inactivated virus. Virol J 2011;8:251; PMID:21600020; http://dx.doi.org/10.1186/1743-422X-8-251
8. Masurel N, Laufer J. A one-year study of trivalent influenza vaccines in primed and unprimed volunteers: immunogenicity, clinical reactions and protection. J Hyg (Lond) 1984;92:263-76; PMID:6736638; http://dx.doi.org/10. 1017/S0022172400064500
9. Ward AE, Hareus AW, Bryett KA, Moore RA. Influenza vaccine: the effects of the 1986/1987 viral strains. Curr Med Res Opin 1987;10:414-21; PMID:3552460; http://dx.doi.org/10.1185/03007998709111111
10. Nicholson KG, Baker DJ, Chakraverty P, Farquhar A, Hurd D, Kent J, et al. Immunogenicity of inactivated influenza vaccine in residential homes for elderly people. Age Ageing 1992;21:182-8; PMID: 1615780; http://dx.doi.org/10. 1093/ageing/21.3.182
11. Xu X, Rocha EP, Regenery HL, Kendal AP, Cox NJ. Genetic and antigenic analyses of influenza A (H1N1) viruses, 1986-1991. Virus Res 1993;28:37-55; PMID:8493812; http://dx.doi.org/10.1016/0168-1702 (93) 90088-5
12. King JC Jr., Lagos R, Bernstein DI, Piedra PA, Kotloff K, Bryant M, et al. Safety and immunogenicity of low and high doses of trivalent live cold-adapted influenza vaccine administered intranasally as drops or spray to healthy children. J Infect Dis 1998;177:1394-7; PMID:9593032; http://dx.doi.org/10.1086/517822
13. Nolan T, Lee MS, Cordova JM, Cho I, Walker RE, August MJ, et al. Safety and immunogenicity of a liveattenuated influenza vaccine blended and filled at two manufacturing facilities. Vaccine 2003;21:1224-31; PMID: 12559802; http://dx.doi.org/10.1016/S0264-410X (02) 00484-X
14. Buxton JA, Skowronski DM, Ng H, Marion SA, Li Y, King A, et al. Influenza revaccination of elderly travelers: antibody response to single influenza vaccination and revaccination at 12 weeks. J Infect Dis 2001;184:188-91; PMID:11424016; http://dx.doi.org/10.1086/322013
15. Bridges CB, Fukuda K, Cox NJ, Singleton J A; Advisory Committee on Immunization Practices. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2001;50(RR-4):1-44; PMID:11334444
16. Owen R, Barr IG, Pengilley A, Liu C, Paterson B, Kaczmarek M; National Influenza Surveillance Scheme. Annual report of the National Influenza Surveillance Scheme, 2007. Commun Dis Intell QRep 2008;32:208-26; PMID:18767420
17. Camilloni B, Neri M, Lepri E, Basileo M, Sigismondi N, Puzelli S, et al. An influenza B outbreak during the 2007/2008 winter among appropriately immunized elderly people living in a nursing home. Vaccine 2010;28:7536-41; PMID:20846530; http://dx.doi.org/10.1016/j.vaccine.2010.08.064
18. McBrayer A, Camp JV, Tapp R, Yamshchikov V, Grimes S, Noah DL, et al. Course of seasonal influenza A/Brisbane/5 9/07 H1N1 infection in the ferret. Virol J 2010;7:149; PMID:20618974; http://dx.doi.org/10.1186/1743-422X-7-149
19. Chen Z, Wang W, Zhou H, Suguitan AL Jr., Shambaugh C, Kim L, et al. Generation of live attenuated novel influenza virus A/California/7/09 (H1N1) vaccines with high yield in embryonated chicken eggs. J Virol 2010;84:44-51; PMID: 19864389; http://dx.doi.org/10.1128/JVI. 02106-09
20. Wang S, Taaffe J, Parker C, Solórzano A, Cao H, Garcfa-Sastre A, et al. Hemagglutinin (HA) proteins from H1 and H3 serotypes of influenza A viruses require different antigen designs for the induction of optimal protective antibody responses as studied by codon-optimized HA DNA vaccines. J Virol 2006;80:11628-37; PMID: 16987975; http://dx.doi.org/10.1128/JVI. 01065-06
21. Caton AJ, Brownlee GG, Yewdell JW, Gerhard W. The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype). Cell 1982;31:417-27; PMID:6186384; http://dx.doi.org/10.1016/0092-8674 (82) 90135-0
22. Jackson DC, Murray JM, White DO, Gerhard WU. Enumeration of antigenic sites of influenza virus hemagglutinin. Infect Immun 1982;37:912-8; PMID:6182104
23. Lubeck M, Gerhard W. Conformational changes at topologically distinct antigenic sites on the influenza A/PR/8/34 virus HA molecule are induced by the binding of monoclonal antibodies. Virology 1982;118:1-7; PMID:6177092; http://dx.doi.org/10.1016/0042-6822 (82) 90313-0
24. Palese P, Garcfa-Sastre A. Influenza vaccines: present and future. J Clin Invest 2002;110:9-13; PMID: 12093881
25. Hancock K, Veguilla V, Lu X, Zhong W, Butler EN, Sun H, et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 2009;361:1945-52; PMID:19745214; http://dx.doi.org/10.1056/ NEJMoa0906453
26. Xu R, Ekiert DC, Krause JC, Hai R, Crowe JE Jr., Wilson I A. Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus. Science 2010;328:357-60; PMID:20339031; http://dx.doi.org/10.1126/science. 1186430
27. Wang S, Parker C, Taaffe J, Solórzano A, Garcfa-Sastre A, Lu S. Heterologous HA DNA vaccine prime-inactivated influenza vaccine boost is more effective than using DNA or inactivated vaccine alone in eliciting antibody responses against H1 or H3 serotype influenza viruses. Vaccine 2008;26:3626-33; PMID: 18538900; http://dx.doi.org/10.1016Zj.vaccine.2008.04.073
28. Zhdanov VM, Lvov DK, Zakstelskaya LY, Yakhno MA, Isachenko VI, Braude NA, et al. Return of epidemic Al (H1N1) influenza virus. Lancet 1978;1:294-5; PMID:75334; http://dx.doi.org/10.1016Z S0l40-6736 (78) 90068-5
29. Kilbourne ED. Influenza pandemics of the 20th century. Emerg Infect Dis 2006;12:9-14; PMID: 16494710; http://dx.doi.org/10.3201/eid1201.051254
30. Steel J, Lowen AC, Wang TT, Yondola M, Gao Q, Haye K, et al. Influenza virus vaccine based on the conserved hemagglutinin stalk domain. MBio 2010;1:e00018-10; PMID:20689752; http://dx.doi.org/10.1128ZmBio.00018-10
31. Palese P, Wang TT. Why do influenza virus subtypes die out? A hypothesis. MBio 2011;2:e00150-11; PMID:21878571; http://dx.doi.org/10.1128/mBio.00150-11
32. Miller MS, Tsibane T, Krammer F, Hai R, Rahmat S, Basler CF, et al. 1976 and 2009 H1N1 influenza virus vaccines boost anti-hemagglutinin stalk antibodies in humans. J Infect Dis 2013;207:98-105; PMID:23087428; http://dx.doi.org/10. 1093/infdis/jis652
33. Wei CJ, Boyington JC, McTamney PM, Kong WP, Pearce MB, Xu L, et al. Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science 2010;329:1060-4; PMID:20647428; http://dx.doi.org/10.1126/science. 1192517
34. Chiu C, Wrammert J, Li GM, McCausland M, Wilson PC, Ahmed R. Cross-reactive humoral responses to influenza and their implications for a universal vaccine. Ann N Y Acad Sci 2013;1283:13-21; PMID:23405860; http://dx.doi.org/10.1111/nyas.12012
35. Wang S, Farfan-Arribas DJ, Shen S, Chou TH, Hirsch A, He F, et al. Relative contributions of codon usage, promoter efficiency and leader sequence to the antigen expression and immunogenicity of HIV-1 Env DNA vaccine. Vaccine 2006;24:4531-40; PMID: 16140431; http://dx.doi.org/10.1016/j.vaccine.2005.08.023
36. Wang S, Pal R, Mascola JR, Chou TH, Mboudjeka I, Shen S, et al. Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E. Virology 2006;350:34-47; PMID:16616287; http://dx.doi.org/10.1016/ j.virol.2006.02.032
37. Wang S, Zhang C, Zhang L, Li J, Huang Z, Lu S. The relative immunogenicity of DNA vaccines delivered by the intramuscular needle injection, electroporation and gene gun methods. Vaccine 2008;26:2100-10; PMID: 18378365; http://dx.doi.org/10.1016/j.vaccine.2008.02.033
38. Vaine M, Wang S, Crooks ET, Jiang P, Montefiori DC, Binley J, et al. Improved induction of antibodies against key neutralizing epitopes by human immunodeficiency virus type 1 gpl20 DNA prime-protein boost vaccination compared to gpl20 protein-only vaccination. J Virol 2008;82:7369-78; PMID:18495775; http://dx.doi.org/1 0.1128/JVI.00562-08
39. Wang S, Hackett A, Jia N, Zhang C, Zhang L, Parker C, et al. Polyvalent DNA vaccines expressing HA antigens of H5N1 influenza viruses with an optimized leader sequence elicit cross-protective antibody responses. PLoS One 2011;6:e28757; PMID:22205966; http://dx.doi.org/10.1371/journal. pone.0028757